Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Olaratumab: a platelet-derived growth factor receptor-[alpha]-blocking antibody for the treatment of soft tissue sarcoma
Ist Teil von
Clinical pharmacology: advances and applications, 2017-01, Vol.9, p.159
Ort / Verlag
Dove Medical Press Limited
Erscheinungsjahr
2017
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase lb/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-[alpha] (PDGFR[alpha])-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable STS. In this review, we discuss the potential role of PDGFR[alpha] signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas. Keywords: olaratumab, sarcoma, PDGFR